Persistent care barriers may lead patients with inflammatory bowel disease (IBD) to ration medication or skip doses. The ...

Data presented at the 2025 Crohn’s and Colitis Congress PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without ...

For older adults with inflammatory bowel disease (IBD), there was no significant difference in the risk of major ...

Despite advances in treatment for inflammatory bowel disease, more than 55% of patients report medication delays, mostly due ...

Low-fiber fruits and vegetables, lean proteins, and foods rich in omega-3 fatty acids tend to be easier on an inflamed gut, ...

The most common reason for delaying or not receiving care was not getting an appointment when they needed one, cited by 39% of respondents. More than half (56%) of patients reported delays in ...

In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...

The Crohn’s & Colitis Foundation and the American Gastroenterological Association (AGA) are excited to host the annual Crohn’s & Colitis Congress®, taking place Feb. 6-8, in San Francisco, CA. This ...

Pharmaceutical ads are difficult to avoid in American television programming and a growing number of them promote a class of ...

Widely used by the food industry, emulsifiers – a type of food additive – are found in many daily foods (sliced bread, ice ...

Though the baseline illness severity was uneven, with more severe patients in the itolizumab arm, the medication showed great ...